A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors
1期
提前终止
NCT03843359
| 适应症 | Neoplasms |
|---|
| 分期 | 1期 |
|---|
| 申办方 | GlaxoSmithKline |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 97 人 |
|---|
| 干预（药物） | GSK3745417, Dostarlimab |
|---|
| 开始日期 | 2019年3月12日 |
|---|
| 完成日期 | 2024年4月4日 |
|---|
| 结果公布日 | 2026年1月8日 |
|---|
摘要
This study aims to evaluate the safety, tolerability, and preliminary clinical activity and establish a recommended dose of GSK3745417 administered alone (Part 1A) or co-administered (Part 2A) with dostarlimab in participants with refractory/relapsed solid tumors. Both parts will consist of a dose escalation phase.
Part 1A: Number of Participants Achieving Dose-limiting Toxicity (DLT) Following Administration of GSK3745417 Alone (Q1W)
Up to 21 Days · Participants
| Part 1A: GSK3745417 0.1 mg (Q1W) | 0 Participants |
|---|
| Part 1A: Japan GSK3745417 0.1 mg (Q1W) | 0 Participants |
|---|
| Part 1A: GSK3745417 0.2 mg (Q1W) | 0 Participants |
|---|
| Part 1A: GSK3745417 0.4 mg (Q1W) | 2 Participants |
|---|
Parts 1A: Number of Participants Achieving DLT Following Administration of GSK3745417 Alone (Q3W)
Up to 29 Days · Participants
| Part 1A: GSK3745417 0.1 mg (Q3W) | 0 Participants |
|---|
| Part 1A: GSK3745417 0.2 mg (Q3W) | 0 Participants |
|---|
Parts 2A: Number of Participants Achieving DLT Following Administration of GSK3745417 in Combination With Dostarlimab (Q1W)
Up to 29 Days · Participants
| Part 2A: GSK3745417 0.1 mg (Q1W) + Dostarlimab | 0 Participants |
|---|
| Part 2A: GSK3745417 0.2 mg (Q1W) + Dostarlimab | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。